ArticleEuropean journal of nuclear medicine and molecular imaging2026
Metformin and renal dosimetry in patients undergoing [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeProstate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) is an established treatment for advanced prostate cancer, but renal radiation exposure remains a major safety concern, as no clinically established nephroprotective strategy exists. Preclinical data suggest metformin to reduce renal radiopharmaceutical retention by interfering with tubular reabsorption. This study aimed to investigate the effect of metformin on renal and tumor dosimetry in PSMA RPT patients.
methods57 patients undergoing PSMA RPT were retrospectively analyzed (n=15 with metformin; n=42 without metformin). The mean kidney absorbed dose (AD) and mean tumor AD (up to three randomly selected osseous metastases per patient) were assessed by post-RPT dosimetry. Total tumor volume (TTV) was evaluated as a potential confounder.
resultsPatients on metformin showed a significantly lower mean kidney AD compared to patients without metformin (median 0.290 vs. 0.367 Gy/GBq; p=0.046). In multiple linear regression analysis, metformin use was independently associated with reduced mean kidney AD, whereas TTV was not a significant predictor. No significant difference in mean tumor AD was observed between groups (0.739 vs. 0.997 Gy/GBq; p=0.215), indicating preserved tumor targeting. No association between tumor burden and mean kidney AD was detected, suggesting independence from tumor sink effect.
conclusionMetformin use was associated with a reduced mean kidney AD in patients undergoing PSMA RPT without affecting tumor ADs. Thus, metformin may represent a promising and widely available strategy to reduce renal radiation exposure and improve the therapeutic index of PSMA-targeted RPT. Prospective studies are warranted to validate these findings and define optimal treatment regimens.
Indexed as
Identifiers
42350617What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.